Routine administration of a single dose of cisplatin ≥ 75 mg/m 2 after short hydration in an outpatient lung-cancer clinic

Bulletin du Cancer

Volumn 99, Issue 4, 2012, Pages

  Lavolé, Armelle ^a   Danel, Sophie ^a   Baudrin, Laurence ^b   Gounant, Valérie ^a   Ruppert, Anne Marie ^a   Epaud, Christelle ^a   Belmont, Laure ^a   Rosencher, Lise ^a   Cadranel, Jacques ^a   Milleron, Bernard ^b  

^a HÔPITAL TENON   (France)

^b Unité de Biostatistiques   (France)

Author keywords

Cisplatin; Lung cancer; Outpatient regimen; Short hydration

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE;

AGED; ARTICLE; COMORBIDITY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FLUID THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 84860114275     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1555     Document Type: Article

References (32)

1. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18 : 106-15. (Pubitemid 30036343)
2. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17 : 3522-30. (Pubitemid 29517923)
3. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20 : 4285-91. (Pubitemid 35266288)
4. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 21 : 3909-17. (Pubitemid 46606203)
5. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350 : 351-60. (Pubitemid 38101630)
6. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7 : 719-27. (Pubitemid 44283661)
7. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352 : 2589-97. (Pubitemid 41007845)
8. Pinzani V, Bressolle F, Haug IJ, et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994; 35 : 1-9. (Pubitemid 24356740)
9. Santoso JT, Lucci 3rd JA, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003; 52 : 13-8. (Pubitemid 36920623)
10. Wiggers JH, Donovan KO, Redman S, et al. Cancer patient satisfaction with care. Cancer 1990; 66 : 610-6. (Pubitemid 20233466)
11. Kleeberg UR, Tews JT, Ruprecht T, et al. Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 2005; 13 : 303-10. (Pubitemid 40674835)
12. Saint-Lorant G, Madelaine J, Galais MP, et al. Hydration of patients treated with cisplatin: practical investigation and establishment of a protocol. Thérapie 2005; 60 : 499-505.
13. Stewart DJ, Dulberg CS, Mikhael NZ, et al. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997; 40 : 293-308. (Pubitemid 27276133)
14. Stewart DJ, Dulberg C, Molepo JM, et al. Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration. Cancer Chemother Pharmacol 1994; 34 : 14-22. (Pubitemid 24194553)
15. Tiseo M, Martelli O, Mancuso A, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-basedchemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007; 93 : 138-44. (Pubitemid 46866703)
16. Brock J, Alberts DS. Safe, rapid administration of cisplatin in the outpatient clinic. Cancer Treat Rep 1986; 70 : 1409-14. (Pubitemid 17005120)
17. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18 : 3390-9.
18. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13 : 1539-49. (Pubitemid 35331451)
19. Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981; 95 : 628-32. (Pubitemid 12231806)
20. Lajer H, Kristensen M, Hansen HH, et al. Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol 2005; 55 : 231-6. (Pubitemid 40142887)
21. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90 : 929-31. (Pubitemid 9244593)
22. Lajer H, Kristensen M, Hansen HH, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 2005; 56 : 535-42. (Pubitemid 41549156)
23. Shord SS, Thompson DM, Krempl GA, et al. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs 2006; 17 : 207-15.
24. Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations. Am J Clin Oncol 1985; 8 : 77-80. (Pubitemid 15059347)
25. Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 1983; 67 : 169-72. (Pubitemid 13110651)
26. Nagai N, Kinoshita M, Ogata H, et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 1996; 39 : 131-7. (Pubitemid 26400671)
27. Nagai N, Ogata H. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 1997; 40 : 11-8. (Pubitemid 27160954)
28. Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5 : 304-9. (Pubitemid 17021616)
29. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12 : 2121-5. (Pubitemid 24356029)
30. Cubillo A, Cornide M, Lopez JL, et al. Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol 2001; 24 : 192-7. (Pubitemid 32323359)
31. Lichtman SM, Buchholtz M, Marino J, et al. Use of cisplatin for elderly patients. Age Ageing 1992; 21 : 202-4.
32. Mor V, Stalker MZ, Gralla R, et al. Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial. J Clin Epidemiol 1988; 41 : 771-85.